HHS Eases Enforcement on Pharmacy Compounding of Six Peptides

by admin
HHS Eases Enforcement on Pharmacy Compounding of Six Peptides

HHS will not act against pharmacies compounding six peptides that meet 10 conditions. Comments are due two weeks after Oct. 30, 2026.

The US Department of Health and Human Services (HHS) will not take action against pharmacies that compound six peptides under strict conditions. Comments on the policy are open for 2 weeks after its Oct. 30, 2026 publication.

HHS published a notice in the Federal Register announcing an interim enforcement policy for six peptide ingredients used in compounded drugs1. It covers state-licensed pharmacies, federal facilities and licensed physicians that mix these drugs for individual patients2. The policy applies while the Food and Drug Administration (FDA) builds the official list of allowed ingredients through formal rulemaking1.

At a glanceDetails
What was publishedInterim enforcement policy, announced as a draft notice
Published on30 October 2026
Who can comment / Who must complyState-licensed pharmacies, federal facilities and licensed physicians that compound drugs
Feedback deadline / Effective dateComments due 2 weeks after 30 October 2026
Final rules / Next milestoneFDA rulemaking on the list of allowed ingredients

What is the peptide policy, and why does it matter?

Compounding means a licensed pharmacist or physician mixes or alters ingredients to make a medicine for one patient2. Compounded drugs are not FDA-approved, so the FDA does not review their safety, effectiveness or quality before sale2. Under federal law, pharmacies may only use bulk ingredients that meet set standards, are part of approved drugs, or appear on an official list2.

The six peptides covered here meet none of those tests yet. HHS says the policy will discourage the widespread use of research-use-only peptides supplied by foreign manufacturers that pose a safety risk to US patients2. It calls the policy a more controlled alternative that advances patient choice while protecting safety2.

Which six peptides are covered?

The policy lists the peptides in its Appendix A2. Each one may be used only in certain forms, set out in Appendix B2.

PeptideAllowed forms
BPC-157 acetateInjection under the skin or into muscle, oral and topical
TB-500 acetateInjection under the skin or into muscle
Epitalon acetateInjection under the skin or into muscle, in intermittent courses
Semax free baseNasal use
KPV acetateTopical and oral
MOTS-c acetateInjection under the skin or into muscle

All six were on the FDA’s "Category 2" list from September 2023 until April 22, 20262. FDA’s drug review center recommended against listing each of them. The Pharmacy Compounding Advisory Committee, an expert panel that advises FDA, voted in favor2.

What pharmacies must do to qualify

HHS will hold back enforcement only when all 10 conditions are met2. The main ones are:

  • The ingredient must come from a facility registered with the FDA, with a valid certificate of analysis2.
  • The original manufacturer must be FDA-registered and follow good manufacturing rules, with its location listed on the certificate2.
  • Each compounded product may contain only one active ingredient from the list2.
  • The only delivery device allowed is an FDA-cleared syringe2.
  • Labels must state: "This is a compounded drug product. Not for resale."2
  • Each drug still needs a valid prescription for a specific patient2.

For oral products, the pharmacy must keep records showing the patient’s body absorbs enough of the peptide2. HHS says oral absorption of peptides is inherently difficult2.

Testing and reporting duties

The certificate of analysis must show test results for identity, purity and strength2. It must also cover harmful contaminants such as endotoxins, heavy metals and microbes2. Appendix B sets out a testing standard listing methods for each quality check2.

Pharmacies must report serious adverse events to MedWatch, the FDA’s safety reporting program2. They must report these whether or not the drug seems to be the cause. Product quality problems, such as contamination, must also be reported, and the states involved must be informed2.

Reporting itemWhat pharmacies must include
Active ingredientName and strength per unit
Original manufacturerName and unique facility identifier
Product formDosage form and route of use

How long the policy lasts

The policy runs until each peptide is addressed in a final rule, either added to or left off the official list2. Future FDA rules may propose adding some or all six peptides, based on the evidence1. HHS may revisit the policy if a safety signal or quality issue arises1.

The notice says the policy creates no rights and does not bind HHS or the public1. Comments go to Docket No. HHS-OASH-2026-0496 on regulations.gov1.

Key terms in plain words

TermMeaning
CompoundingMixing or altering drug ingredients to make a medicine for one patient
Enforcement discretionA choice by the government not to take legal action in set cases
503AThe section of US drug law covering pharmacy compounding
Bulk drug substanceThe raw active ingredient used to make a medicine
Certificate of analysisA lab report confirming an ingredient’s identity, purity and testing
MedWatchThe FDA’s program for reporting drug safety problems

Public comments on the policy are due 2 weeks after its Oct. 30, 2026 publication in the Federal Register1.

Sources

  1. ↩ Federal Register :: Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances
  2. ↩ hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf

You may also like